首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   47363篇
  免费   10410篇
  国内免费   2454篇
医药卫生   60227篇
  2023年   954篇
  2022年   1429篇
  2021年   1361篇
  2020年   1525篇
  2019年   1231篇
  2018年   2890篇
  2017年   1835篇
  2016年   1218篇
  2015年   1184篇
  2014年   690篇
  2013年   1189篇
  2012年   1884篇
  2011年   3596篇
  2010年   1862篇
  2009年   1627篇
  2008年   2213篇
  2007年   2269篇
  2006年   2242篇
  2005年   2232篇
  2004年   3891篇
  2003年   3600篇
  2002年   2566篇
  2001年   2064篇
  2000年   1189篇
  1999年   1517篇
  1998年   1088篇
  1997年   1008篇
  1996年   1402篇
  1995年   738篇
  1994年   806篇
  1993年   620篇
  1992年   705篇
  1991年   665篇
  1990年   545篇
  1989年   459篇
  1988年   359篇
  1987年   357篇
  1986年   323篇
  1985年   260篇
  1984年   173篇
  1983年   140篇
  1979年   147篇
  1977年   121篇
  1975年   162篇
  1974年   149篇
  1973年   176篇
  1972年   145篇
  1971年   140篇
  1970年   126篇
  1969年   144篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
Family history (FH) of cancer is an important factor of increased risk of several cancers. Although the association between FH of cancer and concordant cancer risk has been reported in many previous epidemiological studies, no comprehensive prospective study with adjustment for lifestyle habits has evaluated the association of FH of cancer and concordant cancer risk. We investigated the association between FH of cancer and concordant cancer risk in a Japanese population-based prospective study, initiated in 1990 for cohort I and in 1993 for cohort II. We analyzed data on 103,707 eligible subjects without a history of cancer who responded to a self-administered questionnaire including FH of cancer at baseline. Study subjects were followed through 2012 and analyzed using multivariable-adjusted Cox proportional hazards regression models. During 1,802,581 person-years of follow-up, a total of 16,336 newly diagnosed cancers were identified. Any site (Hazard ratios = 1.11 (95% confidence interval = 1.07–1.15]), esophagus (2.11 [1.00–4.45]), stomach (1.36 [1.19–1.55]), liver (1.69 [1.10–2.61]), pancreas (2.63 [1.45–4.79]), lung (1.51 [1.14–2.00]), uterus (1.93 [1.06–3.51]) and bladder cancers (6.06 [2.49–14.74]) with FH of the concordant cancer were associated with an increased risk compared to those without FH. Our findings suggest that having FH of cancer is associated with an increased risk of several concordant cancer incidences in an Asian population. Enquiring about FH of several types of cancer may be important in identifying groups at high-risk of those cancers.  相似文献   
52.
螺旋断层治疗系统(HT)是一种集调强放射治疗和影像引导放射治疗于一体的放射治疗系统,是目前最先进的放疗设备之一。考虑其与常规直线加速器质量保证的差异,由国家癌症中心/国家肿瘤质控中心提出,多家医疗单位共同参与制定了本指南。指南包括国内医疗机构HT用于临床工作的验收项目、操作制度、应急预案等内容,明确了质量控制的测试方法、评价标准、检测频率。指南结合国内医疗单位实际情况给出了推荐性检测项目,主要包括机械精度、剂量输出与分布、激光定位系统、治疗床运动精度、MVCT影像系统质控检测、临床治疗计划验证等具体实施方法步骤,使得指南具有很强的可操作性。本指南能给临床工作人员提供质量保证技术指导,使HT质量保证工作有章可循,可提高放射治疗的准确性和精度。对国内各医疗机构建立规范HT质量保证体系具有指导意义。  相似文献   
53.
目的:研究非霍奇金淋巴瘤(non-Hodgkin' s lymphoma,NHL)骨髓侵犯患者骨髓病灶中间隙连接蛋白(connexin,Cx)43表达情况。 方法:选取我院确诊的非霍奇金淋巴瘤骨髓侵犯患者26例,骨髓组织中查见呈灶性分布且已通过免疫组化证实为反应性淋巴细胞增生的患者9例,正常骨髓组织10例行免疫组化染色,根据阳性率及阳性程度评分后进行统计学分析。 结果:Cx43在NHL样本中的阳性率(30.8%)低于在反应性淋巴细胞增生样本(88.9%)及正常样本(100%)中的阳性率,差异有统计学意义(P<0.05)。而反应性淋巴细胞增生样本和正常样本间Cx43阳性率无统计学意义(P>0.05),但反应性淋巴细胞增生样本的阳性积分明显低于正常样本(P<0.05)。结论:非霍奇金淋巴瘤骨髓侵犯时病灶处Cx43表达情况显著低于反应性淋巴细胞增生及正常骨髓组织。  相似文献   
54.
Objective: This study investigated the association between fruit and vegetable intake and stomach cancer, with considering the impacts of Helicobacter pylori (H. pylori) infection and tobacco smoking. Methods: A case-control study featuring 80 male incident stomach-cancer cases and 126 male controls was conducted in a general hospital in Viet Nam. A semi-quantitative food frequency and demographic lifestyle questionnaire were used; and venous blood samples were collected to determine H. pylori status by IgG ELISA. The respective associations between fruit and vegetable intake and stomach cancer were examined using unconditional logistic regression analysis with adjustments for possible cofactors. Results: Fruit intake and stomach cancer showed a weak inverse association when this became non-significant after adjusting for H. pylori infection (OR = 0.50, 95%CI: 0.22–1.12, p trend = 0.094). Stratifying by H. pylori status returned a negative trend for fruit intake and stomach cancer among H. pylori-negative participants (OR = 0.21, 95%CI: 0.06–0.69, p trend = 0.010), but no significant interaction for H. pylori-positive participants (OR = 0.76, 95%CI: 0.21–2.68, p trend = 0.670). Vegetable intake and stomach cancer showed no association, regardless of H. pylori status. Compared to ever-smokers with low intake, never-smokers with high vegetable (OR = 0.25, 95% CI: 0.06–0.95) and fruit intake (OR = 0.20, 95%CI: 0.06–0.65) showed the lowest odds of stomach cancer. Conclusions: Fruit, but not vegetable, intake showed a weak inverse association with stomach cancer. H. pylori infection and tobacco-smoking status may influence the protective effects of fruit and vegetable intake on stomach cancer.  相似文献   
55.
目的:研究孤立性肺结节(SPN)胸腔镜术前CT引导下双弹簧圈精准标记定位的应用价值。方法:回顾分析43例SPN胸腔镜术前定位病例资料,包括双弹簧圈组22例,Hook-wire定位组21例。统计双弹簧圈定位的术中、术后并发症,衔接期时间以及作楔形切除所用时间,并将两组结果进行对比分析。结果:两组病例定位均取得成功;双弹簧圈组的气胸发生率(9.0%),肺出血发生率(9.0%),胸痛发生率(9.0%)均低于Hook-wire组,其中肺出血发生率与Hook-wire组比较,差异有统计学意义(P<0.01);衔接时间双弹簧圈组(15.38±8.32)h长于Hook-wire组(4.21±3.29)h,差异有统计学意义(P<0.05);作楔形切除所用时间双弹簧圈组(21.01±7.14)min与Hook-wire组(18.22±5.18)min差异无统计学意义(P>0.05)。结论:采用双微弹簧圈进行SPN胸腔镜手术前精准标记定位安全可靠、效果良好,与Hook-wire定位比较并发症发生率更低,并可获得更长的衔接期,具有较高的应用价值。  相似文献   
56.
Objective: To analyze the effect of sirolimus and sunitinib in blocking the tumor growth and to evaluate the expressions of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor-2 (HER2/neu) after treated with sirolimus and sunitinib. Methods: Thirty-two female Sprague Dawley rats at age 21-days old were administered intraperitoneally with N-Methyl-N-Nitroso Urea (NMU), dosed at 70mg/kg body weight. The rats were divided into 4 groups; Group 1 (Control, n=8), Group 2 (Sirolimus, n=8), Group 3 (Sunitinib, n=8) and Group 4 (Sirolimus+Sunitinib, n=8), being treated twice when the tumor reached the size of 14.5±0.5 mm and subsequently sacrificed after 5 days. The protein expressions of ER, PgR and HER2/neu of the tumor tissues were evaluated by using immunohistochemistry analysis. Results: Treatment with sirolimus alone lowered expressions of ER and PgR of breast cancer and reduced tumor size. There was no significant difference of ER and PgR expressions between control and sunitinib treated tumor. Sunitinib treated tumors reduce in diameter after the first treatment, however the diameter increases after the second treatment. Histologically, sunitinib treated tumor did not show any aggressive invasive carcinoma of no special type (NST) histological subtypes. In addition, all NMU-induced tumors are HER2/neu-negative scoring. Conclusion: Sirolimus is neither synergistic nor additive with sunitinib for breast cancer treatment.  相似文献   
57.
58.
Background: The standard of care in high grade glioma (HGG) is maximal safe surgical resection followed by adjuvant radiotherapy (RT) with/without chemotherapy. For anaplastic gliomas, studies have shown use of procarbazine, lomustine, vincristine (PCV) improves overall survival (OS) and progression free survival (PFS). Currently, there is substantial evidence that molecular markers strongly predict prognosis and response to treatment. Methods: Between January 2016 to January 2018, 42 patients were accrued and followed up till April 2019. The primary end points were to correlate molecular markers with response to therapy in terms of OS and PFS in HGG. The secondary end point was to evaluate frequency of 1p/19q codeletion, IDH 1 mutation, ATRX deletion and p53 in HGG patients. Results: The median age was 46 years (range 18-67) with M:F ratio 30:12. The frequency of IDH1 mutation,1p/19q codeletion, p53 mutation and ATRX mutation were 42.8%, 16.6%, 42.8% and 14.2% respectively. All the seven patients with 1p/19q codeletion had IDH1 mutation. Median follow up was 22 months. The 20-months PFS for different mutations were as follows; IDH1-mutated vs wild type: 53.6% vs 29.8%; p-0.035, 1p/19q codeleted vs non-codeleted: 85.7% vs 62.3%; p-0.011, p53 wild type vs mutated 32.1% vs 35.6%; p-0.035 and ATRX lost vs retained: 55.6% vs 53.3%; p- 0.369. The 20-months OS for IDH1 mutated vs wild type: 82.4% vs 30.6%; p-0.014, 1p/19q codeleted vs non-codeleted: 85.7% vs 65.8%; p-0.104, p53 wild-type vs mutated 45.5% vs 73.9%; p-0.036 and ATRX lost vs retained: 100% vs 60.3%; p-0.087. Conclusion: Codeletion of 1p/19q with IDH1 mutation in HGG is associated with a significantly favourable PFS. However, larger studies with longer follow up are required to evaluate OS and PFS in all the molecular subgroups.  相似文献   
59.
Objective: A dimeric neolignan, bishonokiol A (BHNKA) isolated from Magnolia grandiflora, significantly inhibits the proliferation of human breast cancer cells. However, the exact mechanism of BHNKA induced breast cancer cell death is unknown. In this study, we investigated the pharmacological mechanism underlying BHNKA induced MCF-7 cell death. Methods: Cell viability measurement was performed by the MTT assay. Flow cytometry with PI staining, DAPI staining, and electron microscopy were used to analyze cellular death modes. In addition, western blotting, siRNA transfection, ATP assay, and fluorescence microscopy were used to determine the mechanism of BHNKA induced MCF-7 cell death. Results: BHNKA induced cell death by apoptosis, necroptosis and autophagy at the same concentration and time in MCF-7 cells, and electron microscopy confirmed these results. The mechanism of BHNKA triggered apoptosis and autophagy in MCF-7 cells was primarily due to an increase in the Bax/Bcl-2 ratio and simultaneous up-regulation of LC3-II protein expression, respectively. BHNKA induced necroptosis by activation of the RIP1-RIP3-MLKL necroptosis cascade, up-regulation of cyclophilin D (CypD) protein expression to stimulate ROS generation. We further demonstrated that siRNA-mediated down-regulation of CypD protected against BHNKA induced cell death. Conclusions: These results suggest that BHNKA may be a potential lead compound for development as an anti-breast cancer agent for induction of multiple cell death pathways.  相似文献   
60.
Background: Tobacco is one of the leading causes of preventable deaths. It is both a major social and health problem. According to National Sample Survey Organization of Government of India about 20 million children of ages 10-14 are estimated to be tobacco-addicted. There are grave consequences of tobacco both socially and also on health thus it is of utmost importance to understand the factors leading to its use and to plan strategies to reduce its intake. However, the health implications of this social issue in a rural context have not been explored. Aims and Objective: this study makes an attempt to explore the health and social implications of tobacco usage by the children below the age of 14 years in hamlet. Materials and Methods:  The present study employed a qualitative study design. Data was collected using focus group discussion and in-depth interview of key informants. Thematic analysis for exploring the explicit and implicit meanings within the data was done. The themes which emerged were knowledge about tobacco and the various products available, children and parents’ tobacco use and habits, the health and social implication of tobacco use, reasons for tobacco use by the children. Results: It was found tobacco use by the children was very common in the community. Parent, peer pressure, sibling pressure were found to be playing important role in the initiation of tobacco habit by the child. Further illiteracy and lack of awareness was also lead to tobacco use among children. Conclusion: The study identifies education and awareness of parents about the ill-effects of tobacco play an important role as parents act as role model for their children, thus equal stress should be laid in improving the parental habits. Even raising the prices of tobacco products can help in controlling this habit.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号